Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.50 |
| ▸ | IKZF3 | Q9UKT9 | 14/20 | 0.50 |
| ▸ | TNF | P01375 | 6/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | IL1B | P01584 | 3/20 | 0.46 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20766690 | 1.00 | CRBN (0.50) | CRBNIKZF3TNFHDAC3HDAC1 | |
| SCHEMBL28408660 | 0.89 | CRBN (0.56) | CRBNIKZF3TNFHDAC3HDAC1 | |
| SCHEMBL20766693 | 0.88 | CRBN (0.40) | CRBNIKZF3TNFHDAC3HDAC1 | |
| SCHEMBL20766665 | 0.88 | CRBN (0.40) | CRBNIKZF3TNFHDAC3HDAC1 | |
| SCHEMBL20766688 | 0.88 | CRBN (0.62) | CRBNIKZF3TNFHDAC3HDAC1 | |
| SCHEMBL20766686 | 0.88 | CRBN (0.62) | CRBNIKZF3TNFHDAC3HDAC1 | |
| SCHEMBL20766636 | 0.87 | CRBN (0.68) | CRBNIKZF3TNFHDAC3HDAC1 | |
| SCHEMBL2255598 | 0.87 | CRBN (0.68) | CRBNIKZF3TNFHDAC3HDAC1 | |
| SCHEMBL20767171 | 0.86 | CRBN (0.51) | CRBNIKZF3TNFHDAC3HDAC1 | |
| SCHEMBL20766739 | 0.83 | CRBN (0.47) | CRBNIKZF3TNFIL1BIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927104-B2 | Ether compounds and uses thereof | BIOTHERYX, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200231582-A1 | ETHER COMPOUNDS AND USES THEREOF | BIOTHERYX, INC. | 2020-07-23 | — | — | US | disclosed |
| EP-3672955-A1 | ETHER COMPOUNDS AND USES THEREOF | Biotheryx Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019040274-A1 | ETHER COMPOUNDS AND USES THEREOF | BIOTHERYX, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927104-B2 | Ether compounds and uses thereof | EPCAM, ICAM1, SELE | CRBN 379/4885IKZF3 122/4885TNF 62/4885 |
| US-20200231582-A1 | ETHER COMPOUNDS AND USES THEREOF | EPCAM, ICAM1, SELE | CRBN 379/4885IKZF3 122/4885TNF 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.